VICTOR RIVERA to Enzyme Inhibitors
This is a "connection" page, showing publications VICTOR RIVERA has written about Enzyme Inhibitors.
Connection Strength
0.237
-
Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors. Oncotarget. 2015 Oct 20; 6(32):32646-55.
Score: 0.093
-
Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors. J Med Chem. 2013 Feb 14; 56(3):1023-40.
Score: 0.077
-
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood. 2004 Oct 15; 104(8):2532-9.
Score: 0.043
-
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice. Oncotarget. 2016 May 17; 7(20):29011-22.
Score: 0.024